Introduction
Vancomycin is one of the most potent agents against lifethreatening Gram-positive bacterial infections affecting patients hospitalized in intensive care units, especially when multi-resistant bacterial isolates are involved. 1 Standard doses suggested by the manufacturer and dosing nomograms represent the two most common methods for initiating vancomycin dosing regimens. Several investigators have developed various dosing nomograms, [2] [3] [4] [5] [6] most of which use a fixed vancomycin distribution volume and consider creatinine clearance as the most accurate predictor of vancomycin clearance. However, as inter-and intrapatient variability in vancomycin disposition have been found to be 0.87 mg/L; P < 0.01), despite no major change in bodyweight or estimated creatinine clearance being observed. We postulate that these drugs with important haemodynamic effects may enhance vancomycin clearance by inducing an improvement in cardiac output and/or renal blood flow, and/or by interacting with the renal anion transport system, and thus by causing an increased glomerular filtration rate and renal tubular secretion. Given the wide simultaneous use of vancomycin and dopamine and/or dobutamine and/or frusemide in patients admitted to intensive care units, clinicians must be aware of possible subtherapeutic serum vancomycin concentrations when these drugs are coadministered. Therefore, therapeutic drug monitoring (TDM) for the pharmacokinetic optimization of vancomycin therapy is strongly recommended in these situations. wide, 7, 8 an individualized approach to vancomycin dosing regimens through the use of measured serum concentrations to avoid vancomycin-related nephro-and ototoxicity 9, 10 and to improve efficacy has been strongly advocated. 10, 11 This practice of therapeutic drug monitoring (TDM) is considered mandatory in the management of vancomycin therapy when certain pathophysiological conditions (e.g. impairment of renal function, burns, iv drug abuse) 12 or other risk factors (e.g. coadministration of cyclosporin, aminoglycosides, amphotericin B) 13 coexist. Therapeutic peak (20-40 mg/L) and trough (5-10 mg/L) serum ranges have been identified and are accepted w o r l dw i d e . 1 4 , 1 5 Recently, the design of individualized dosage regimens for vancomycin has been improved by means of Bayesian principles. [16] [17] [18] These methods have been validated in various pathophysiological conditions, such as critically ill patients with haematological malignancies and in intensive care units, and appear to be suitable for routine clinical practice. 19, 20 On these bases, we wanted to evaluate retrospectively a Bayesian pharmacokinetic approach for predicting vancomycin concentrations to individualize its dosing regimen in critically ill patients admitted to an intensive care unit following cardiothoracic surgery, this being a population with possible unstable cardiac output and rapidly changing renal function. More relevantly, the coadministration of some drugs with substantial haemodynamic effects, such as dopamine, dobutamine and frusemide, may commonly be required for temporary inotropic support and to preserve renal function after cardiac surgical procedures. Therefore, the main purpose of our study was to assess the possible influence of these haemodynamically active coadministered drugs on vancomycin pharmacokinetics.
Patients and methods
We evaluated retrospectively data collected from 18 (ten male, eight female) critically ill patients (Table I) admitted to intensive care units following cardiac surgical procedures at the Cardiothoracic Surgery Department of the S. M. Misericordia Udine Hospital over a 1 year period. All the eligible patients received vancomycin to treat documented acute infections caused by staphylococci (Staphylococcus aureus and coagulase-negative staphylococci) and were cotreated with at least one drug with important haemodynamic effects: six with dopamine plus dobutamine plus frusemide; six with dobutamine plus frusemide; one with dopamine plus frusemide; and five with frusemide alone. All these drugs were administered by continuous iv infusion. Creatinine clearance (Cl Cr ) was estimated by means of the Cockcroft & Gault formula. 21 TDM of vancomycin was performed after at least 48 h of therapy and then repeated every 1-5 days throughout the treatment period. Blood samples were collected a few minutes before the next drug administration to determine the trough serum concentration (C min ss ) and 30 min after the end of a 1 h intermittent vancomycin infusion to determine the peak serum concentration (C max ss ). After centrifugation, serum samples were analysed within 2 h by means of a fluorescence polarization immunoassay (TDx, Abbott Laboratories, Abbott Park, IL, USA). The interday and intraday coefficient of variation of the assay was 10%. As all the patients had normal renal function (serum creatinine 1.5 mg/dL), no overestimation of vancomycin concentration as a result of antibiotically inactive vancomycin crystalline degradation product (CDP-1) was expected. 22 Each patient's characteristics together with his or her individual vancomycin dosage regimen and TDM results were analysed by means of a pharmacokinetic computer program (PKS, Abbott Pharmacokinetic System, Abbott Laboratories) 23 based on the Bayesian approach, to predict what would have been the best individualized vancomycin dosing regimen to reach the therapeutic peak and trough serum ranges. Indeed, as vancomycin exhibits time-dependent bactericidal activity, [24] [25] [26] the time during which free serum concentration persists above the MIC for the pathogen involved should be considered the major pharmacokinetic-pharmacodynamic factor determining its in vivo bactericidal activity. 27, 28 Therefore, as some bacterial isolates may show intermediate sensitivity (MIC 2-4 mg/L) and vancomycin is about 50% serum protein bound, 29 our pharmacokinetic approach was focused on attaining a vancomycin steady-state serum trough concentration as close as possible to the upper limit of the therapeutic range (10 mg/L), to maximize efficacy while minimizing potential toxicological risks. The total daily dosage was in 2-4 intermittent 1 h iv infusions, the amount of each single dose being 500 mg or less. Vancomycin administered dosage regimens predicted by the Bayesian method (D a ) were then compared retrospectively with Moellering's nomogram-based dosages (D M ) 5 to assess possible major differences in vancomycin dosing and to evaluate to what extent the estimated creatinine clearance as predictor of vancomycin clearance in such a population could be considered accurate. In agreement with other 
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Results
The mean (± S.D.) Bayesian predicted administered dosage regimens of vancomycin (D a ) required to attain the desired peak (21.69 ± 4.95 mg/L) and steady upper limit serum trough concentration (9.12 ± 1.26 mg/L) (C min ss ) were significantly higher than those suggested by Moellering (Figure 2) , despite no major difference in attained vancomycin C min ss (9.22 ± 1.33 mg/L versus 8.99 ± 1.26 mg/L; P 0.75; CI -1.50 to 1.10) or estimated Cl Cr (1.23 ± 0.49 mL/min/kg versus 1.21 ± 0.24 mL/min/kg; P 0.95; CI -0.41 to 0.39) being found between the former group and the latter group. The relationship between the administered dosages of vancomycin, the Moellering's nomogrambased dosages, the estimated Cl Cr and the trough concentrations reached during the whole TDM observation period in the D a D M group are shown in Table II . Of the patients requiring a D a much larger than D M , four (patients V-VIII) had the haemodynamically active drugs suspended owing to clinical improvement before the discontinuation of the vancomycin treatment. It is worth noting that the withdrawal of these cotreatments was followed by a sudden substantial increase in the vancomycin C min ss ( 
Discussion
The findings suggest a major role played by coadministered drugs with important haemodynamic effects on vancomycin pharmacokinetics in intensive care unit patients admitted following cardiac surgery. The well-known wide intra-and inter-individual pharmacokinetic variability of vancomycin might account only partially for the high vancomycin dosages per kg required during the period of cotreatment in these patients. In fact, whereas the average differences between D a and D M were moderate ( 20%) in ten patients (D a D M group), they were much higher (21-90%) in the other eight patients (D a D M group), despite the fact that no major differences in attained C min ss or estimated Cl Cr were found between the two groups. Moreover, as no patients had major fluid overload, the high vancomycin dosages required seem unlikely to be due to an increased volume of distribution. Therefore, we postulate that drugs with important haemodynamic effects may enhance vancomycin clearance by inducing an improvement in cardiac output and/or renal blood flow. The significant vancomycin dosage reductions required by four D a D M patients to avoid an exaggerated vancomycin total body exposure and to lower trough concentration within the therapeutic range the day after the withdrawal of the haemodynamically active drugs is in agreement with this hypothesis. As far as the possible mechanism of this enhanced clearance is concerned, it has to be taken into account that Moellering's nomogram is based on Cl Cr and the latter is considered to be a surrogate marker of glomerular filtration rate. Therefore, the wide differences between D a and D M observed in the D a D M group suggest that the enhanced vancomycin clearance may be induced not only by an increased glomerular filtration rate, but also by a significant augmentation of its renal tubular secretion, considering that nonrenal routes account only slightly for vancomycin clearance. The observation that no major changes in serum creatinine or estimated Cl Cr occurred in those four D a D M patients continuing vancomycin treatment after the withdrawal of the haemodynamically active drugs further strengthens this hypothesis.
Indeed, as the observations of Rodvold et al., 6 Rybak et al. 29 and Golper et al. 31 indicate that tubular secretion may be considered a significant component of vancomycin's net renal excretion, an increase of renal blood flow and/or an interaction with the renal anion transport system induced by these coadministered drugs may explain our findings.
Many investigators have previously documented that dopamine, dobutamine and frusemide may exert direct or indirect substantial haemodynamic effects on renal blood flow.
Dopamine may increase cardiac output through stimul a tion of adrenergic receptors and shows important vasodilating effects at the renal level in a dose-dependent fashion, mainly secondary to a stimulation of renal vascular dopaminergic D 1 receptors. 32, 33 No definitive relationship between dobutamine and haemodynamic effect on renal blood flow has been demonstrated. Conflicting opinions have been expressed, with some papers suggesting that dobutamine may enhance renal blood flow secondary to increases in cardiac contractility and cardiac output and perhaps to an arterial vasodilating effect both in humans and in animals. 34, 35 Several investigators documented that glomerular filtration rate and renal blood flow significantly increased after frusemide administration both in animals and in humans, probably by releasing prostaglandin E 2 .
36-39 Furthermore, Nivoche et al. 40 showed that in rabbits the administration of frusemide enhanced vancomycin tubular secretion without any effect on the filtered load.
Accordingly, all of these haemodynamically active drugs (dopamine, dobutamine, frusemide) may enhance renal blood flow and theoretically vancomycin renal clearance. Indeed, it should be noted that this effect did not have the same importance in all subjects, but was mainly seen in patients receiving simultaneously at least two of these drugs by iv continuous infusion (dobutamine plus frusemide in four cases and dopamine plus dobutamine plus frusemide in another four cases). These findings could be explained by a synergic effect between dopamine and/or dobutamine and/or frusemide, on renal blood flow. Moreover, the degree of their induced effect on vancomycin renal clearance may be extremely variable, seeing that it was higher in some patients. Indeed, our patients were given different doses of these haemodynamically active drugs from day to day according to clinical status. Because of this, no definitive relationship between the haemodynamic effect and the administered dose could be found.
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In conclusion, our findings show a wide vancomycin inter-individual pharmacokinetic variability in intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures, and suggest that the estimated Cl Cr should not always be considered as an accurate predictor of vancomycin clearance. In fact, some cotreated patients required much higher vancomycin dosages than those estimated on the basis of the creatinine clearance only. Given the wide simultaneous use of vancomycin and dopamine and/or dobutamine and/or frusemide in patients admitted to intensive care units, clinicians must be aware of possible subtherapeutic serum vancomycin concentrations when these drugs are coadministered. Therefore, TDM for the pharmacokinetic optimization of vancomycin therapy is strongly recommended in these situations. On these bases, we are going to begin a prospective study to evaluate this potential interaction.
